FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025743982> ?p ?o ?g. }

• W3025743982 endingPage "731.e9" @default.
• W3025743982 startingPage "731.e1" @default.
• W3025743982 abstract "Background Surgical site infection after surgery for gynecologic cancer increases morbidity. Prophylactic closed incision negative pressure therapy has shown promise in reducing infectious wound complications across many surgical disciplines. Objective This study aimed to determine whether closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy compared with standard dressings. Study Design This was a retrospective case-control study of patients undergoing laparotomy for known or suspected gynecologic cancer from Jan. 1, 2017, to Feb. 1, 2020. Patients were matched in a 1:3 ratio (closed incision negative pressure therapy to standard dressing) by body mass index, age, diabetes, bowel surgery, smoking, and steroid use. Surgical site infection was defined according to the Centers for Disease Control and Prevention. Multivariable logistic regression using backward selection was performed. Results Of the 1223 eligible patients undergoing laparotomy, 64 (5.2%) received closed incision negative pressure therapy dressings and were matched to 192 (15.7%) controls. There were no differences in medical comorbidities (P>.05), site or stage of malignancy (P>.05), duration of surgery (P=.82), or surgical procedures (P>.05). Use of closed incision negative pressure therapy was associated with reduction in all adverse wound outcomes (20.3% vs 40.1%; P<.001). In particular, closed incision negative pressure therapy was associated with a significant reduction in both superficial incisional surgical site infections (9.4% vs 29.7%; P<.001) and deep incisional surgical site infections (0.0% vs 6.8%; P=.04). In multivariable analysis, use of closed incision negative pressure therapy was associated with significant reduction in the incidence of superficial incisional infections alone (odds ratio, 0.29; 95% confidence interval, 0.12–0.73; P=.008) and both superficial and deep incisional infections (odds ratio, 0.29; 95% confidence interval, 0.12–0.71; P=.007). Conclusion Use of prophylactic closed incision negative pressure therapy after laparotomy in gynecologic oncology patients was found to be associated with reduced superficial incisional and deep incisional infections compared with standard dressings. Furthermore, closed incision negative pressure therapy was associated with reduction in all other adverse wound outcomes. Closed incision negative pressure therapy may be considered for surgical site infection prevention in high-risk gynecologic oncology patients undergoing laparotomy. Surgical site infection after surgery for gynecologic cancer increases morbidity. Prophylactic closed incision negative pressure therapy has shown promise in reducing infectious wound complications across many surgical disciplines. This study aimed to determine whether closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy compared with standard dressings. This was a retrospective case-control study of patients undergoing laparotomy for known or suspected gynecologic cancer from Jan. 1, 2017, to Feb. 1, 2020. Patients were matched in a 1:3 ratio (closed incision negative pressure therapy to standard dressing) by body mass index, age, diabetes, bowel surgery, smoking, and steroid use. Surgical site infection was defined according to the Centers for Disease Control and Prevention. Multivariable logistic regression using backward selection was performed. Of the 1223 eligible patients undergoing laparotomy, 64 (5.2%) received closed incision negative pressure therapy dressings and were matched to 192 (15.7%) controls. There were no differences in medical comorbidities (P>.05), site or stage of malignancy (P>.05), duration of surgery (P=.82), or surgical procedures (P>.05). Use of closed incision negative pressure therapy was associated with reduction in all adverse wound outcomes (20.3% vs 40.1%; P<.001). In particular, closed incision negative pressure therapy was associated with a significant reduction in both superficial incisional surgical site infections (9.4% vs 29.7%; P<.001) and deep incisional surgical site infections (0.0% vs 6.8%; P=.04). In multivariable analysis, use of closed incision negative pressure therapy was associated with significant reduction in the incidence of superficial incisional infections alone (odds ratio, 0.29; 95% confidence interval, 0.12–0.73; P=.008) and both superficial and deep incisional infections (odds ratio, 0.29; 95% confidence interval, 0.12–0.71; P=.007). Use of prophylactic closed incision negative pressure therapy after laparotomy in gynecologic oncology patients was found to be associated with reduced superficial incisional and deep incisional infections compared with standard dressings. Furthermore, closed incision negative pressure therapy was associated with reduction in all other adverse wound outcomes. Closed incision negative pressure therapy may be considered for surgical site infection prevention in high-risk gynecologic oncology patients undergoing laparotomy." @default.
• W3025743982 created "2020-05-21" @default.
• W3025743982 creator A5003422625 @default.
• W3025743982 creator A5005911289 @default.
• W3025743982 creator A5031819902 @default.
• W3025743982 creator A5055338760 @default.
• W3025743982 creator A5062339261 @default.
• W3025743982 creator A5083179216 @default.
• W3025743982 creator A5083444425 @default.
• W3025743982 date "2020-11-01" @default.
• W3025743982 modified "2023-09-26" @default.
• W3025743982 title "Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy" @default.
• W3025743982 cites W1794393634 @default.
• W3025743982 cites W1976832839 @default.
• W3025743982 cites W2001228378 @default.
• W3025743982 cites W2025225533 @default.
• W3025743982 cites W2027875330 @default.
• W3025743982 cites W2061368480 @default.
• W3025743982 cites W2067604798 @default.
• W3025743982 cites W2075409723 @default.
• W3025743982 cites W2093274439 @default.
• W3025743982 cites W2115955924 @default.
• W3025743982 cites W2180086139 @default.
• W3025743982 cites W2234654806 @default.
• W3025743982 cites W2290123478 @default.
• W3025743982 cites W2319310467 @default.
• W3025743982 cites W2461755890 @default.
• W3025743982 cites W2512587053 @default.
• W3025743982 cites W2553196508 @default.
• W3025743982 cites W2560030408 @default.
• W3025743982 cites W2616395980 @default.
• W3025743982 cites W2622076712 @default.
• W3025743982 cites W2669049036 @default.
• W3025743982 cites W2737839336 @default.
• W3025743982 cites W2791414310 @default.
• W3025743982 cites W2810782768 @default.
• W3025743982 cites W2884292851 @default.
• W3025743982 cites W2893251783 @default.
• W3025743982 cites W2922317032 @default.
• W3025743982 cites W2990326861 @default.
• W3025743982 cites W4235976125 @default.
• W3025743982 doi "https://doi.org/10.1016/j.ajog.2020.05.011" @default.
• W3025743982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32417358" @default.
• W3025743982 hasPublicationYear "2020" @default.
• W3025743982 type Work @default.
• W3025743982 sameAs 3025743982 @default.
• W3025743982 citedByCount "9" @default.
• W3025743982 countsByYear W30257439822020 @default.
• W3025743982 countsByYear W30257439822021 @default.
• W3025743982 countsByYear W30257439822022 @default.
• W3025743982 countsByYear W30257439822023 @default.
• W3025743982 crossrefType "journal-article" @default.
• W3025743982 hasAuthorship W3025743982A5003422625 @default.
• W3025743982 hasAuthorship W3025743982A5005911289 @default.
• W3025743982 hasAuthorship W3025743982A5031819902 @default.
• W3025743982 hasAuthorship W3025743982A5055338760 @default.
• W3025743982 hasAuthorship W3025743982A5062339261 @default.
• W3025743982 hasAuthorship W3025743982A5083179216 @default.
• W3025743982 hasAuthorship W3025743982A5083444425 @default.
• W3025743982 hasConcept C141071460 @default.
• W3025743982 hasConcept C142724271 @default.
• W3025743982 hasConcept C204787440 @default.
• W3025743982 hasConcept C2779210606 @default.
• W3025743982 hasConcept C2779232120 @default.
• W3025743982 hasConcept C2780435969 @default.
• W3025743982 hasConcept C2780778865 @default.
• W3025743982 hasConcept C3020304732 @default.
• W3025743982 hasConcept C71924100 @default.
• W3025743982 hasConceptScore W3025743982C141071460 @default.
• W3025743982 hasConceptScore W3025743982C142724271 @default.
• W3025743982 hasConceptScore W3025743982C204787440 @default.
• W3025743982 hasConceptScore W3025743982C2779210606 @default.
• W3025743982 hasConceptScore W3025743982C2779232120 @default.
• W3025743982 hasConceptScore W3025743982C2780435969 @default.
• W3025743982 hasConceptScore W3025743982C2780778865 @default.
• W3025743982 hasConceptScore W3025743982C3020304732 @default.
• W3025743982 hasConceptScore W3025743982C71924100 @default.
• W3025743982 hasIssue "5" @default.
• W3025743982 hasLocation W30257439821 @default.
• W3025743982 hasOpenAccess W3025743982 @default.
• W3025743982 hasPrimaryLocation W30257439821 @default.
• W3025743982 hasRelatedWork W1828076862 @default.
• W3025743982 hasRelatedWork W1979647207 @default.
• W3025743982 hasRelatedWork W1987190207 @default.
• W3025743982 hasRelatedWork W2327936246 @default.
• W3025743982 hasRelatedWork W2383553971 @default.
• W3025743982 hasRelatedWork W2749999355 @default.
• W3025743982 hasRelatedWork W3025743982 @default.
• W3025743982 hasRelatedWork W4294379278 @default.
• W3025743982 hasRelatedWork W4306253774 @default.
• W3025743982 hasRelatedWork W4319264772 @default.
• W3025743982 hasVolume "223" @default.
• W3025743982 isParatext "false" @default.
• W3025743982 isRetracted "false" @default.
• W3025743982 magId "3025743982" @default.
• W3025743982 workType "article" @default.